The national Health Technology Assessment (“HTA”) by the Irish National Centre for Pharmacoeconomics (“NCPE”) of Novartis’ Itvisma was the first HTA in which, according to the NCPE, an EU Joint Clinical Assessment (“JCA”) “was used to inform” its assessment.
The HTA was conducted as a Rapid Review, . The NCPE concluded that Itvisma should not be considered for reimbursement at the submitted price as it was not considered to be cost-effective.